# US 2025/0146035 A1 · Biocatalyst and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146035 A1
- Document ID: US20250146035A1
- Status: Published application
- Kind: A1
- Application number: 19/012,148
- Filed: 2025-01-07
- Published: 2025-05-08
- Earliest claimed: 2018-01-31
- Assignees: The Regents of the University of Michigan
- Applicants: The Regents of the University of Michigan
- Inventors: Haoming ZHANG
- Web page: https://patentgrep.com/patent/US20250146035A1

## CPC

- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12P 17/167: {Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs}
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Y 106/02004: NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present invention relates to methods for synthesizing mixed disulfide conjugates of thienopyridine compounds with a genetically engineered variant of cytochrome P450 BM3 or CYP102A1 as a catalyst, and belongs to the field of chemical synthesis.

## Claims

### Claim 1

A mutant CYP102A1 enzyme capable of catalyzing conjugation between 2-oxo thienopyridine and heterocyclic thiols in the presence of a reducing reagent.

### Claim 2 (depends on 1)

The mutant CYP102A1 enzyme of claim 1, wherein the catalyzing of conjugation between 2-oxo thienopyridine and heterocyclic thiols in the presence of a reducing reagent results in the generation of mixed disulfide conjugates of thienopyridine compounds.

### Claim 3 (depends on 1)

The mutant CYP102A1 enzyme of claim 1, wherein the catalyzing of conjugation between 2-oxo thienopyridine and heterocyclic thiols in the presence of a reducing reagent selectively generates cis stereoisomers of the mixed disulfide conjugates of thienopyridine compounds.

### Claim 4 (depends on 1)

The mutant CYP102A1 enzyme of claim 1, wherein the reducing agent is NADPH or NADH.

### Claim 5 (depends on 1)

The mutant CYP102A1 enzyme of claim 1, wherein the enzyme comprises one or more of the following amino acid mutations within SEQ ID NO: 2: A82F, L188Q, R47L, F87V, T365N, H116Q, K31T, S56R, A135S, V299D, I458F, P481H, and W1046A.

### Claim 6 (depends on 1)

The mutant CYP102A1 enzyme of claim 1, wherein the enzyme comprises an amino acid sequence having a specific set of mutations recited in Table 2.

### Claim 7 (depends on 1)

The mutant CYP102A1 enzyme of claim 1, wherein the enzyme comprises nucleic acid having at least 99% homology with SEQ ID NO: 1.

### Claim 8 (depends on 1)

The mutant CYP102A1 enzyme of claim 1, wherein the enzyme comprises nucleic acid having at least 100% homology with SEQ ID NO: 3.

### Claim 9 (depends on 1)

A method for synthesizing cis stereoisomers of mixed disulfide conjugates of thienopyridine compounds, comprising mixing a 2-oxo thienopyridine moiety, a heterocyclic thiol moeity, and the mutant CYP102A1 enzyme of claim 1 in the presence of a reducing reagent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the reducing agent is NADPH or NADH.

### Claim 11 (depends on 9)

The method of claim 9, wherein the 2-oxo thienopyridine moiety is represented by
wherein R1 is either Chlorine or Fluorine; wherein R2 is H, COOCH3, or COCHCH2CH2.

### Claim 12 (depends on 9)

The method of claim 9, wherein the heterocyclic thiol moiety is represented by R3-SH; wherein R3 is selected from 3-nitropyridine-2-thiol, 2-mercaptopyridine, 2-mercapto-6-methylpyridine, 5-chloropyridine-2-thiol, 2-mercapto-5-trifluoromethyl-pyridine, 3-(trifluoromethyl) pyridine-2-thiol, 2-mercaptopyridine-3-carbonitrile, 4,6-dimethyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile, 2-quinolinethiol, 1-amino-3-mercaptoisoquinoline, 6-chloropyridazine-3-thiol, and 2,5-dimethylfuran-3-thiol.

### Claim 13 (depends on 9)

The method of claim 9, wherein the mixing occurs at ambient temperature.

### Claim 14 (depends on 9)

The method of claim 9, wherein the mixing occurs for a time period between twenty and sixty minutes.

### Claim 15 (depends on 9)

The method of claim 9, wherein the mutant CYP102A1 enzyme is comprised within a bacterial cytosolic fraction.

### Claim 16 (depends on 9)

The method of claim 9, wherein the amount of mutant CYP102A1 enzyme is between approximately 0.1 and 1 μM.

### Claim 17 (depends on 9)

The method of claim 9, wherein the mixing results in the generation of approximately 100 mg of cis stereoisomers of mixed disulfide conjugates of thienopyridine compounds per liter of the 2-oxo thienopyridine moiety, the heterocyclic thiol moeity, the mutant CYP102A1 enzyme, and the reducing agent.

### Claim 18 (depends on 1)

A kit comprising a 2-oxo thienopyridine moiety, a heterocyclic thiol moeity, and the mutant CYP102A1 enzyme of claim 1.

### Claim 19 (depends on 18)

The kit of claim 18, further comprising a reducing reagent.

### Claim 20 (depends on 19)

The kit of claim 19, wherein the reducing agent is NADPH or NADH.

### Claim 21 (depends on 18)

The method of claim 18, wherein the 2-oxo thienopyridine moiety is represented by
wherein R1 is either Chlorine or Fluorine; wherein R2 is H, COOCH3, or COCHCH2CH2.

### Claim 22 (depends on 18)

The method of claim 18, wherein the heterocyclic thiol moiety is represented by R3-SH; wherein R3 is selected from 3-nitropyridine-2-thiol, 2-mercaptopyridine, 2-mercapto-6-methylpyridine, 5-chloropyridine-2-thiol, 2-mercapto-5-trifluoromethyl-pyridine, 3-(trifluoromethyl)pyridine-2-thiol, 2-mercaptopyridine-3-carbonitrile, 4,6-dimethyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile, 2-quinolinethiol, 1-amino-3-mercaptoisoquinoline, 6-chloropyridazine-3-thiol, and 2,5-dimethylfuran-3-thiol.

### Claim 23 (depends on 9)

A pharmaceutical composition comprising a compound generated with the method of claim 9 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein said pharmaceutical composition is configured for intravenous administration.

### Claim 25 (depends on 9)

A method of treating, ameliorating, or preventing a cardiovascular disease in a patient comprising administering to said patient a therapeutically effective amount of a compound generated with the method of claim 9.

### Claim 26 (depends on 25)

The method of claim 25, wherein said administration is selected from the group consisting of oral administration and intravenous administration.

### Claim 27 (depends on 25)

The method of claim 25, wherein said cardiovascular disease is selected from the group consisting of coronary artery disease, peripheral vascular disease, atherothrombosis, and cerebrovascular disease.

### Claim 28 (depends on 25)

The method of claim 25, wherein said compound reduces aggregation of platelets.

### Claim 29 (depends on 28)

The method of claim 28, wherein said reduces aggregation of said platelets occurs through irreversible binding to P2Y12 receptors.

### Claim 30 (depends on 28)

The method of claim 28, wherein said reduces aggregation of said platelets occurs through blocking ADP receptors.

### Claim 31 (depends on 25)

The method of claim 25, further comprising co-administration of at least one agent selected from the group consisting of a HMG-CoA reductase inhibitor, an ACE Inhibitor, a Calcium Channel Blocker, a Platelet Aggregation Inhibitor, a Polyunsaturated Fatty Acid, Fibric Acid Derivative, a Bile Acid Sequestrant, an Antioxidant, a Thrombolytic Agent, and an Antianginal Agent.
